News

Haoxin Holdings Limited Announces Pricing of Initial Public Offering
Haoxin Holdings Limited ("Haoxin" or the "Company") (NasdaqCM: HXHX), a provider of temperature-controlled truckload services and urban delivery services ...
Why did Lilly data for oral GLP-1 boost Structure and Metsera?
Structure Therapeutics (GPCR) stock and Metsera (MTSR) stock soar as Eli Lilly (LLY) reports promising Phase 3 results for ...
Reklaim Ltd. Reports Record 2024 Revenue and Positive EBITDA
Revenue Up 24%, Gross Margin Reaches 82%, Operating Cash Flow Up 282% Year-Over-Year NEW YORK, April 17, 2025 /PRNewswire/ - Reklaim (TSXV: MYID) (OTC: MYIDF), ...
uniQure jumps on FDA breakthrough tag for Huntington’s disease drug
Qure (QURE) stock surges 39% as FDA grants Breakthrough Therapy designation for AMT-130, a gene therapy for Huntington’s disease. Read more here.
F/m Investments Files Amended Application for ETF Share Class Relief
F/m Investments ("F/m"), a $17 billion investment firm and innovative provider of exchange-traded funds (ETFs), today announced it has amended and updated its application with the U.S. Securities and ...
UniQure Shares Soar After Latest FDA Designation for Huntington's Disease Treatment
Gene therapy developer uniQure shares soared 46% in premarket trading after its treatment for Huntington's disease received breakthrough therapy designation from the Food and Drug Administration.